Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00070837
Status:
COMPLETED
Last Update Posted:
2007-07-13
First Post:
2003-10-08
Brief Title:
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 12 Dose Escalation Trial of Multiple Doses of MLN2704 DM1 Conjugated Monoclonal Antibody MLN591 in Subjects With Metastatic Androgen-Independent Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2007-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine the highest dose of MLN2704 that can be given multiple times safely to patients with prostate cancer and to identify any side effects associated with taking the drug This study will also evaluate how MLN2704 is taken up broken down and eliminated by the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None